Congratulations to our Top Doctors!
30 year old stroke survivor recalls the scariest day of her life!
Read Christie Flemming's amazing story here.
Tackling Concussions in Youth Football. Are Children Safe?
See Dr. Weisman discuss the recent article from Wake Forest University that demonstrates brain injury without concussion in children playing football.
Abington Physician featured on CBS News discussing new trial for people suffering from dementia
Dr. David Weisman featured on CBS news discussing a new clinical trial for Lewy Body Dementia.
Abington Neurologist discusses the future of Alzheimer's on NBC 10.
Abington Neurological Associate's Dr. David Weisman sits down with NBC10’s Keith Jones to discuss the effects Alzheimer’s Disease has and the NOBLE clincal trial.
Abington Neurological Associates physician recognized for work in Alzheimer's Disease
The Alzheimer's Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California San Diego. The ADCS is a major initiative for Alzheimer's disease (AD) clinical studies in the Federal government, addressing treatments for both cognitive and behavioral symptoms. This is part of the NIA Division of Neuroscience program's effort to facilitate the discovery, development and testing of new drugs for the treatment of AD and also is part of the Alzheimer's Disease Prevention Initiative. Dr. David Weisman of Abington Neurological Associates was recognized as an investigator in this important effort.
New treatments offer unique opportunities to treat Alzheimer’s Disease
Abington Neurologist discusses biosimilars and biologics in the Philadelphia Business Journal
Biosimilars are biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of controlled gene expression.
Physicians should be made aware if pharmacies chose to switch a physician prescribed biologic product for a biosimilar. Read the op-ed article in the Philadelphia Business Journal.
Abington Memorial Hospital is given the elite status of being a Comprehensive Stroke Center.
Abington Neurological Associates physicians help Abington Memorial Hospital to become designated a comprehensive stroke center – a certification earned by fewer than 1 percent of hospitals nationwide.
As the first Pennsylvania stroke center to earn the highly regarded Gold Seal of Approval from the Joint Commission, AMH consistently earns awards that distinguish itself in the Philadelphia region for its stroke services.
These honors include the American Stroke Association/American Heart Association’s Gold Plus Performance Achievement Award for stroke quality-of-care.
Dr. Dan Gzesh is proud to serve as the director of this center, known as the Diamond Stroke Center.
Abington Neurological Associates physician testifies on behalf of physicians and patients before the Pennsylvania House of Representatives
Abington Neurological Associates physician testifies before the House of Representatives in Harrisburg, PA regarding House Bill 746 that addresses biosimilar medications.
Biosimilars are biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of recombinant DNA or controlled gene expression methods.
In short, this bill ensures that patients and physicians are made aware if the pharmacist substitutes a biosimilar product.
For further information, please click to see the Pennsylvania Medical Society update.
Abington Neurological Associates physician serves as co-author on national expert panel publication in headache
Abington Neurological Associates physician is co-author of an seminal expert consensus article in the academic journal, Headache, reviewing nerve blocks for headache disorders.
Please click for details.
Abington Neurological Associates physician is again named “Top Doc” by Philadelphia Magazine
Abington Neurological Associates physician is once again named Top Doc by Philadelphia Magazine for 2013.